A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2547-2555

  Zangemeister Wittke, Uwe ^a   Leech, Siân H ^a   Olie, Robert A ^a   Simões Wüst, A Paula ^a   Gautschi, Oliver ^a   Luedke, Gerd H ^a   Natt, François ^b   Häner, Robert ^b   Martin, Pierre ^b   Hall, Jonathan ^b   Nalin, Carlo M ^c   Stahel, Rolf A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE; PROTEIN BCL 2; PROTEIN BCL X;

APOPTOSIS; ARTICLE; BASE MISPAIRING; DRUG UPTAKE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY;

APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CASPASE 3; CASPASES; CELL NUCLEUS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENES, BCL-2; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; POLYMERASE CHAIN REACTION; PROPIDIUM; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034096268     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Chao, D. T., and Korsmeyer, S. J. BCL-2 family: regulators of cell death. Annu. Rev. Immunol., 16: 395-419, 1998.
2. Kojima, H., Endo, K., Moriyama, H., Tanaka, Y., Alnemri, E. S., Slapak, C. A., Teicher, B., Kufe, D., and Datta, R. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J. Biol. Chem., 273: 16647-16650, 1998.
3. Simonian, P. L., Grillot, D. A., and Nunez, G. Bcl-2 and Bel-XL can differentially block chemotherapy-induced cell death. Blood, 90: 1208-1216, 1997.
4. Gottschalk, A. R., Boise, L. H., Thompson, C. B., and Quintans, J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc. Natl. Acad. Sci. USA, 91: 7350-7354, 1994.
5. Han, Z., Chatterjee, D., Early, J., Pantazis, P., Hendrickson, E. A., and Wyche, J. H. Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL. Cancer Res., 56: 1621-1628, 1996.
6. Gewirtz, A. M., Sokol, D. L., and Ratajczak, M. Z. Nucleic acid therapeutics: state of the art and future prospects. Blood, 92: 712-736, 1998.
7. Ziegler, A., Luedke, G. H., Fabbro, D., Altmann, K. H., and Zangemeister-Wittke, U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Nat. Cancer Inst., 89: 1027-1036, 1997.
8. Ackermann, E. J., Taylor, J. E., Narayana, R., and Bennett C. F. The role of antiapoptotic bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J. Biol. Chem., 274: 11245-11252, 1999.
9. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van, Elsas, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998.
10. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., Distefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. Bcl-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet, 349: 1137-1141, 1997.
11. Matveeva, O., Felden, B., Tsodikov, A., Johnston, J., Monia, B. P., Atkins, J. F., Gesteland, R. F., and Freier, S. M. Prediction of antisense oligonucleotide efficacy by in vitro methods. Nat. Biotechnol., 16: 1374-1375, 1998.
12. Schuler, G. D., Altschul, S. F., and Lipman, D. J. A workbench for multiple alignment construction and analysis. Proteins, 9: 180-190, 1991.
13. Matzura, O., and Wennborg, A. RNAdraw: an integrated program for RNA secondary structure calculation and analysis under 32-bit Microsoft Windows. Comput. Appl. Biosci., 12: 247-249, 1996.
14. De Mesaeker, A., Häner, R., Martin, P., and Moser, H. E. Antisense oligonucleotides. Accounts Chem. Res., 28: 366-374, 1995.
15. Martin, P. A new access to 2′-O-alkylated ribonucleosides and properties of 2′-O-alkylated oligoribonucleotides. Helv. Chim. Acta, 78: 486-504, 1995.
16. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., and Freier, S. M. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem., 268: 14514-14522, 1993.
17. Cheng, E. H., Kirsch, D. G., Clem, R. J., Ravi, R., Kastan, M. B., Bedi, A., Ueno, K., and Hardwick, J. M. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science (Washington DC), 278: 1966-1968, 1997.
18. Clem, R. J., Cheng, E. H., Karp, C. L., Kirsch, D. G., Ueno, K., Takahashi, A., Kastan, M. B., Griffin, D. E., Earnshaw, W. C., Veliuona, M. A., and Hardwick, J. M. Modulation of cell death by Bcl-XL through caspase interaction. Proc. Natl. Acad. Sci. USA. 95: 554-559, 1998.
19. Olie, R. A., Durrieu, F., Cornillon, S., Loughran, G., Gross, J., Earnshaw, W. C., and Golstein, P. Apparent caspase independence of programmed cell death in Dictyostelium. Current Biology, 8: 955-958, 1998.
20. Arriola, E. L., Rodriguez, L. A., Hickman, J. A., and Chresta, C. M. Bcl-2 overexpression results in reciprocal down-regulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene, 18: 1457-1464, 1999.
21. Reeve, J. G., Xiong, J., Morgan, J., and Bleehen, N. M. Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer, 73: 1193-1200, 1996.
22. Roggli, V. L., Vollmer, R. T., Greenberg, S. D., McGavran, M. H., Spjut, H. J., and Yesner, R. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum. Pathol., 16: 569-579, 1985.
23. Mabry, M., Nelkin, B. D., Falco, J. P., Barr, L. F., and Baylin, S. B. Transitions between lung cancer phenotypes-implications for tumor progression. Cancer Cells, 3: 53-58, 1991.
24. ZangemeisterWittke, U., and Ziegler, A. Bcl-2 antisense therapy for cancer: the art of persuading tumor cells to commit suicide. Apoptosis, 3: 67-74, 1998.
25. Stein, C. A., Subasinghe, C., Shinozuka, K., and Cohen, J. S. Physiochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res., 16: 3209-3221, 1988.
26. Leech, S. A., Olie, R. A., Gautschi, O., Simões-Wüst, A. P., Tschopp, S., Häner, R., Hall, J., Stahel, R. A., and Zangemeister-Wittke, U. Induction of apoptosis in lung cancer cells following bcl-xL antisense treatment. Int. J. Cancer, in press, 2000.
27. Zangemeister-Wittke, U., Schenker, T., Luedke, G. H., and Stahel, R. A. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small cell lung cancer cell lines. Br. J. Cancer, 78: 1035-1042, 1998.
28. Olopade, O. I., Adeyanju, M. O., Safa, A. R., Hagos, F., Mick, R., Thompson, C. B., and Recant, W. M. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am., 3: 230-237, 1997.
29. Liu, J. R., Fletcher, B., Page, C., Hu, C., Nunez, G., and Baker, V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol. Oncol., 70: 398-403, 1998.
30. Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nunez, G., Krammer, P. H., Peter, M. E., and Debatin, K. M. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res., 57: 4956-4964, 1997.